AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM
Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 5 a.m. PT on Tuesday, Nov. 26, 2024, to ...
New Drug Causes 20 Percent Weigh Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
Amgen decline on MariTide data could be due to lack of more details
Two Street analysts weigh in on Amgen's phase 2 MariTide data, saying that they would like to see additional details on the ...
Amgen share price plummets despite Phase II weight loss success
Amgen reported 20% weight loss in its MariTide Phase II study results, but a 10% drop in share price suggests investors had ...
Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed
Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...
MM&M20h
Amgen’s MariTide achieves 20% weight loss, but Wall Street remains unimpressed
Amgen released the long-awaited results from its study of weight loss injection MariTide and the results — while promising — ...
Amgen’s MariTide only differentiation seems to be dosing frequency, says Leerink
Leerink notes that Amgen’s Phase 2 MariTide showed “up to ~20% average weight loss at 52 weeks” in nondiabetic obese/overweight patients, which is roughly on par with the hi ...
BioSpace4h
‘Bulls Disappointed’ as Amgen’s MariTide Demonstrates 20% Weight Loss
Amgen’s MariTide results are at the lower end of investors’ expectation of 20% to 25% weight loss. The much-anticipated ...
BioPharma Dive3h
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on long-awaited results for the company’s monthly MariTide shot, which is ...
Amgen’s MariTide shows up to 20% average weight loss in Phase 2 study
Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart cafraglutide, ...
FierceBiotech6h
Amgen’s monthly obesity drug matches competition in phase 2, but investors are unimpressed
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
The Pharma Letter4h
Amgen’s MariTide falls short of analyst expectations in obesity
The Californian company earlier announced positive data at 52 weeks in a double-blind, dose-ranging Phase II study with ...